Biofrontera Inc. to Present at the 34th Annual Roth Conference
09 mars 2022 11h08 HE
|
Biofrontera Inc.
WOBURN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT
01 févr. 2022 08h47 HE
|
Biofrontera Inc.
WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is...
Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and Beyond
18 janv. 2022 09h25 HE
|
Biofrontera Inc.
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today...
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
13 janv. 2022 08h45 HE
|
Biofrontera Inc.
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today...
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises
30 déc. 2021 08h45 HE
|
Biofrontera Inc.
WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through...
Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®
06 déc. 2021 09h00 HE
|
Biofrontera Inc.
WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
30 nov. 2021 09h20 HE
|
Biofrontera Inc.
Conference call at 4:30 p.m. Eastern time today WOBURN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the...
Biofrontera strengthens commercial focus with reorganization of its US business
06 janv. 2020 09h00 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced a new...